{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T23:24:44Z","timestamp":1788477884124,"version":"build-2803163510"},"reference-count":22,"publisher":"Elsevier BV","issue":"13","license":[{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,8,12]],"date-time":"2025-08-12T00:00:00Z","timestamp":1754956800000},"content-version":"am","delay-in-days":254,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The French Journal of Urology"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1016\/j.fjurol.2024.102699","type":"journal-article","created":{"date-parts":[[2024,7,20]],"date-time":"2024-07-20T23:37:47Z","timestamp":1721518667000},"page":"102699","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Comparing efficacy and safety of in-house gemcitabine to mitomycin for bladder instillation in intermediate-risk NMIBC"],"prefix":"10.1016","volume":"34","author":[{"given":"Carla","family":"Abou Chaaya","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Said","family":"Ourfali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chloe","family":"Marchand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camille","family":"Merienne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alain","family":"Ruffion","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hugo","family":"Brouzes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadia","family":"Abid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabrice","family":"Pirot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Colombel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.fjurol.2024.102699_bib0115","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/j.euo.2022.05.005","article-title":"Intermediate-risk non-muscle-invasive Bladder cancer: updated consensus definition and management recommendations from the International Bladder Cancer Group","volume":"5","author":"Tan","year":"2022","journal-title":"Eur Urol Oncol"},{"issue":"15","key":"10.1016\/j.fjurol.2024.102699_bib0120","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1016\/j.purol.2022.08.006","article-title":"French AFU Cancer Committee Guidelines\u00a0\u2013\u00a0update 2022\u20132024: non-muscle-invasive bladder cancer (NMIBC)","volume":"32","author":"Neuzillet","year":"2022","journal-title":"Prog Urol"},{"issue":"1","key":"10.1016\/j.fjurol.2024.102699_bib0125","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.eururo.2021.08.010","article-title":"European Association of Urology guidelines on non-muscle-invasive Bladder cancer (Ta, T1, and carcinoma in situ)","volume":"81","author":"Babjuk","year":"2022","journal-title":"Eur Urol"},{"issue":"6","key":"10.1016\/j.fjurol.2024.102699_bib0130","first-page":"CD009294","article-title":"Intravesical gemcitabine for non-muscle invasive bladder cancer","volume":"6","author":"Han","year":"2021","journal-title":"Cochrane Database Syst Rev"},{"issue":"4","key":"10.1016\/j.fjurol.2024.102699_bib0135","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1200\/JCO.2008.20.8199","article-title":"Randomized phase III trial on gemcitabine versus mytomicin in recurrent superficial bladder cancer: evaluation of efficacy and tolerance","volume":"28","author":"Addeo","year":"2010","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.fjurol.2024.102699_bib0140","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1016\/j.eururo.2016.01.006","article-title":"Results of a randomised controlled trial comparing intravesical chemohyperthermia with mitomycin C versus Bacillus Calmette-Gu\u00e9rin for adjuvant treatment of patients with intermediate- and high-risk non-muscle-invasive Bladder cancer","volume":"69","author":"Arends","year":"2016","journal-title":"Eur Urol"},{"issue":"1B","key":"10.1016\/j.fjurol.2024.102699_bib0145","first-page":"765","article-title":"Impact of intravesical chemotherapy on recurrence rate of recurrent superficial transitional cell carcinoma of the bladder: results of a meta-analysis","volume":"21","author":"Huncharek","year":"2001","journal-title":"Anticancer Res"},{"issue":"2","key":"10.1016\/j.fjurol.2024.102699_bib0150","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/S1040-8428(03)00075-1","article-title":"Intravesical therapy of superficial bladder cancer","volume":"47","author":"Malmstr\u00f6m","year":"2003","journal-title":"Crit Rev Oncol Hematol"},{"issue":"3","key":"10.1016\/j.fjurol.2024.102699_bib0155","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/j.eururo.2004.05.001","article-title":"Phase II study to investigate the ablative efficacy of intravesical administration of gemcitabine in intermediate-risk Superficial Bladder Cancer (SBC)","volume":"46","author":"Gontero","year":"2004","journal-title":"Eur Urol"},{"issue":"1","key":"10.1016\/j.fjurol.2024.102699_bib0160","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1186\/s12894-020-00610-9","article-title":"Intravesical gemcitabine versus mitomycin for non-muscle invasive bladder cancer: a systematic review and meta-analysis of randomized controlled trial","volume":"20","author":"Li","year":"2020","journal-title":"BMC Urol"},{"issue":"4","key":"10.1016\/j.fjurol.2024.102699_bib0165","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1016\/j.eururo.2020.12.033","article-title":"European Association of Urology (EAU) prognostic factor risk groups for non-muscle-invasive Bladder cancer (NMIBC) incorporating the WHO 2004\/2016 and WHO 1973 classification systems for grade: an update from the EAU NMIBC guidelines panel","volume":"79","author":"Sylvester","year":"2021","journal-title":"Eur Urol"},{"issue":"2","key":"10.1016\/j.fjurol.2024.102699_bib0170","first-page":"123","article-title":"Intravesical Gemcitabine versus intravesical Bacillus Calmette-Guerin for the treatment of intermediate-risk non-muscle invasive Bladder cancer: a randomized controlled trial","volume":"20","author":"Ansari Djafari","year":"2023","journal-title":"Urol J"},{"key":"10.1016\/j.fjurol.2024.102699_bib0175","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.2147\/DDDT.S164704","article-title":"Gemcitabine hydrochloride microspheres used for intravesical treatment of superficial bladder cancer: a comprehensive in vitro\/ex vivo\/in vivo evaluation","volume":"12","author":"Karavana","year":"2018","journal-title":"Drug Des Devel Ther"},{"issue":"11","key":"10.1016\/j.fjurol.2024.102699_bib0180","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1248\/cpb.58.1461","article-title":"Microemulsions for intravesical delivery of gemcitabine","volume":"58","author":"Tsai","year":"2010","journal-title":"Chem Pharm Bull"},{"key":"10.1016\/j.fjurol.2024.102699_bib0185","unstructured":"Design and evaluation of an intravesical delivery system for superficial bladder cancer: preparation of gemcitabine HCl-loaded chitosan\u00a0\u2013\u00a0thioglycolic acid nanoparticles and comparison of chitosan\/poloxamer gels as carriers\u00a0\u2013\u00a0PMC [Internet]. [cit\u00e9 12 janv 2024]. Available: https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC4610785\/."},{"issue":"1","key":"10.1016\/j.fjurol.2024.102699_bib0190","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.ijpharm.2013.04.058","article-title":"UPEC biomimickry at the urothelial barrier: lectin-functionalized PLGA microparticles for improved intravesical chemotherapy","volume":"450","author":"Neutsch","year":"2013","journal-title":"Int J Pharm"},{"key":"10.1016\/j.fjurol.2024.102699_bib0195","article-title":"Intravesical chemohyperthermia vs. Bacillus Calmette-Guerin instillation for intermediate- and high-risk non-muscle invasive Bladder cancer: a systematic review and meta-analysis","volume":"8","author":"H","year":"2021","journal-title":"Front Surg"},{"issue":"4","key":"10.1016\/j.fjurol.2024.102699_bib0200","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1007\/s00345-022-03928-1","article-title":"Recirculating hyperthermic intravesical chemotherapy with mitomycin C (HIVEC) versus BCG in high-risk non-muscle-invasive bladder cancer: results of the HIVEC-HR randomized clinical trial","volume":"40","author":"Guerrero-Ramos","year":"2022","journal-title":"World J Urol"},{"key":"10.1016\/j.fjurol.2024.102699_bib0205","unstructured":"Electromotive instillation of mitomycin immediately before transurethral resection for patients with primary urothelial non-muscle invasive bladder cancer: a randomised controlled trial\u00a0\u2013\u00a0PubMed [Internet]. [cit\u00e9 12 janv 2024]. Available: https:\/\/pubmed.ncbi.nlm.nih.gov\/21831711\/."},{"issue":"3","key":"10.1016\/j.fjurol.2024.102699_bib0210","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1097\/JU.0000000000002740","article-title":"Sequential intravesical Gemcitabine and Docetaxel for bacillus Calmette-Gu\u00e9rin-Na\u00efve high-risk nonmuscle-invasive Bladder cancer","volume":"208","author":"McElree","year":"2022","journal-title":"J Urol"},{"issue":"5","key":"10.1016\/j.fjurol.2024.102699_bib0215","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1097\/JU.0000000000000688","article-title":"Multi-institution evaluation of sequential Gemcitabine and Docetaxel as rescue therapy for non-muscle invasive Bladder cancer","volume":"203","author":"Steinberg","year":"2020","journal-title":"J Urol"},{"issue":"5","key":"10.1016\/j.fjurol.2024.102699_bib0220","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/j.euo.2023.06.011","article-title":"Sequential intravesical Gemcitabine and Docetaxel is an alternative to Bacillus Calmette-Gu\u00e9rin for the treatment of intermediate-risk non-muscle-invasive Bladder cancer","volume":"6","author":"Tan","year":"2023","journal-title":"Eur Urol Oncol"}],"container-title":["The French Journal of Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2950393024001566?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2950393024001566?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,11,22]],"date-time":"2024-11-22T00:43:44Z","timestamp":1732236224000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2950393024001566"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12]]},"references-count":22,"journal-issue":{"issue":"13","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["S2950393024001566"],"URL":"https:\/\/doi.org\/10.1016\/j.fjurol.2024.102699","relation":{},"ISSN":["2950-3930"],"issn-type":[{"value":"2950-3930","type":"print"}],"subject":[],"published":{"date-parts":[[2024,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comparing efficacy and safety of in-house gemcitabine to mitomycin for bladder instillation in intermediate-risk NMIBC","name":"articletitle","label":"Article Title"},{"value":"The French Journal of Urology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.fjurol.2024.102699","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"102699"}}